The aberrant activation of AXL was showed to be required for the development of erlotinib resistance in EGFR-mutant NSCLC models both in vitro and in vivo via Akt, MAPK or NF-κB downstream signaling [70]. The gene discussed is AXL; the disease is non-small cell lung carcinoma.